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ABSTRACT
Vaccines constitute a potential new therapeutic ap-
proach for a range of human cancers. Unlike other
therapeutics, vaccines initiate a dynamic process in
the host immune system that can be exploited with
subsequent therapies. Indeed, recent preclinical and
clinical studies with cancer vaccines have provided
evidence that this unique therapeutic modality should
lead to consideration of new paradigms in both clini-
cal trial design and endpoints and in combination
therapies. The present article reviews and sets out a
rationale for these new paradigms, with a focus on
prostate cancer.
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1. INTRODUCTION
Cancer vaccines initiate a dynamic process by acti-
vating the host’s own immune system—an approach
that differentiates them from other, more conventional
therapies. This process could potentially influence
the evaluation of patients’ responses to initial therapy
and to subsequent therapies post vaccination. No
therapeutic cancer vaccine has yet been approved by
the U.S. Food and Drug Administration (FDA), but
the field of cancer vaccines is currently in a state of
active preclinical and clinical investigation. Recent
preclinical and clinical studies with cancer vaccines
have provided evidence that this unique therapeutic
modality should lead to consideration of new para-
digms in both clinical trial design and endpoints and
in combination therapies. Cancer vaccines may well
ultimately be employed for the therapy of many types
of cancer (Table I).
2. DISCUSSION
2.1 Tumour Response Versus Patient Response
In our opinion, cancer vaccines will become the thera-
peutic modality in which greater emphasis will be
placed on “patient response” than on “tumour re-
sponse,” two phenomena that are not always mutu-
ally inclusive.
Standardization of response criteria is of course
critical for any given clinical trial; however, it must
be emphasized that the use of only one criterion for
all therapeutics, cancer types, and disease stages can
be misleading. In 2000, an international committee
formulated the Response Evaluation Criteria in Solid
Tumors (RECIST) as a means of measuring tumour re-
sponse 1,2. The use of RECIST criteria has served the
oncology community well in evaluating passive thera-
peutic modalities such as chemotherapeutic agents
and radiation therapy. With the advent of new tar-
geted therapies, including cancer vaccines, the sole
use of RECIST criteria has now been called into ques-
tion by several cooperative groups, among others 2–5.
An excellent example is found in the evaluation of
sorafenib (Nexavar: Onyx Pharmaceuticals,
Emeryville, CA, U.S.A.) in clinical trials of patients
with advanced renal cell carcinoma. In those trials,
increases in patient survival were seen with low
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TABLE I New paradigms for vaccine efficacy as compared with
those for conventional therapeutics
Efficacy of vaccines can be enhanced by biologic adjuvants
Tumour cell phenotype can be altered to enhance vaccine
efficacy
Vaccines induce a dynamic process (important in combination
scheduling)
As compared with tumour response (RECIST), patient response
(survival) may be the more important criterion for efficacy
RECIST = Response Evaluation Criteria in Solid Tumors.
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tumour response levels and only 1 complete response
from among 451 patients 6. It is clear from these re-
sults and others that RECIST criteria do not always ad-
equately assess the clinical benefit to patients.
A recent article 7 characterized stable disease and
longer-than-expected survival as “soft criteria” in the
evaluation of cancer vaccines as compared with the
“standard” or RECIST criteria of measuring tumour
volume. In contrast, the tumour volume reduction
observed in some melanoma patients treated with
adoptive T-cell transfer techniques was proposed as
a modality that satisfies RECIST criteria. The findings
arising from the use of antigen-specific adoptive-
transfer T-cell techniques are important and ex-
tremely innovative, and the therapy may well benefit
certain subsets of patients. However, consideration
must be given to the fact that, over the course of
20 years,
• no randomized trial of adoptive cell transfer tech-
niques using either lymphokine-activated killer
cells or tumour-infiltrating lymphocytes has dem-
onstrated a statistically significant survival ben-
efit over that seen with interleukin 2 (IL-2)
alone 8–10;
• no randomized trial using adoptive transfer of
“antigen-specific” T cells to demonstrate a sur-
vival benefit in any patient population has been
conducted; and
• studies of adoptive transfer of antigen-specific
T cells have been carried out only in select insti-
tutions and have not been successfully translated
to enable numerous cancer centres to carry out
multicentre randomized trials 8.
In addition, other factors associated with this
therapy must be considered, including toxicities and
the labour- and cost-intensive efforts required by this
therapy. It is thus suggested that adoptive-transfer
T-cell therapy may be more applicable to patients with
advanced disease, and that vaccine therapy may be
more applicable to patients with a lower tumour bur-
den or at an earlier stage in the disease process. As
will be discussed shortly in this article, several ran-
domized clinical trials have been conducted with a
range of cancer vaccines that are now showing evi-
dence of clinical benefit in terms of patient survival.
It is thus important to consider different paradigms
for measuring patient benefit when various therapeu-
tics are used in varying patient populations.
2.2 Vaccine Trials in Prostate Cancer
An earlier review 11 listed 21 clinical trials in which
a range of cancer vaccines provided evidence of clini-
cal benefit in various patient populations. Here, we
discuss recent clinical findings resulting from the use
of several different vaccine types in the therapy of
prostate cancer.
Prostate cancer is a disease well suited for an
analysis of the efficacy of cancer vaccines for sev-
eral reasons:
• Prostate tumours are relatively slow-growing.
• Recurrence is often diagnosed early in the dis-
ease state.
• The doubling time of serum prostate specific an-
tigen (PSA) acts as a surrogate marker for disease
prognosis and outcome 12–14 (Arlen PM, Bianco
F, Dahut WL, et al. Prostate-specific Antigen
Working Group’s guidelines on PSA doubling
time. Submitted to J Urol).
• After definitive primary therapy (surgery or ra-
diation, or both), few standard-of-care therapies
exist that achieve long-lasting therapeutic effects.
• A range of prostate cancer–associated antigens
have been identified and characterized.
• Early clinical studies have shown that patients
will mount immune responses to the prostate can-
cer–associated antigens post vaccination.
Perhaps the most mature of the prostate cancer
vaccines in terms of clinical trials is sipuleucel-T.
Sipuleucel-T consists of autologous antigen-present-
ing cells and a fusion protein composed of prostatic
acid phosphatase and granulocyte–macrophage
colony–stimulating factor (GM-CSF). A placebo-con-
trolled, randomized phase III trial using sipuleucel-T
(Table II) was recently conducted 15 in patients with
metastatic, asymptomatic (without cancer-related
pain), hormone-refractory prostate cancer (HRPC). Pro-
gression-free survival (the primary endpoint) was not
statistically significant, but overall survival between
the vaccine and the placebo groups (25.9 months vs.
21.4 months) reached statistical significance (p =
0.01).
Another prostate cancer vaccine employed in ad-
vanced clinical trial testing is Gvax (Cell Genesys,
San Francisco, CA, U.S.A.). Gvax consists of two ir-
radiated allogeneic prostate cancer cell lines engi-
neered to secrete GM-CSF. Its mode of action is proposed
as the uptake of the ex vivo X-irradiated tumour cells
by APC and cross-presentation of tumour-associated
antigens to T cells in draining lymph nodes. Two
phase II clinical studies have now been completed in
patients with asymptomatic metastatic HRPC 16–18. In
the first trial (n = 34), Gvax was given at two dose
levels. In the second trial, using the same patient popu-
lation (n = 80), vaccine was given to five dose-level
cohorts: two low-dose cohorts (n = 33), one interme-
diate-dose cohort (n = 25), and two high-dose cohorts
(n = 22). In the low-dose cohorts, the median survival
of patients was 23.1 months; in the intermediate-dose
cohort, it was 20.0 months. The median survival of
the high-dose cohorts is 35 months (Table II). No dose-
limiting toxicities were observed in either trial.
Onyvax-P vaccine (Onyvax, London, U.K.) is
another whole tumour-cell vaccine for prostateSCHLOM et al.
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cancer that is also demonstrating promising clinical
results. Onyvax-P consists of three irradiated alloge-
neic prostate cell lines. These cell lines have been
shown to express a broad range of prostate- and pros-
tate cancer–associated antigens, in a manner similar
to the Gvax vaccine. A phase II Onyvax-P trial has
now been completed in HRPC patients 23. Of 26 patients,
11 showed a statistically significant prolonged reduc-
tion in PSA velocity, and no patient had a statistically
significant increase in PSA velocity post vaccination.
Mean time to tumour progression was 58 weeks as
compared with the approximately 28 weeks seen with
recent studies of other agents and with historical con-
trol values. Artificial neural network analysis of the
immunologic profiles of cytokines correlated with the
PSA velocity responses 23.
Several trials with vaccines using poxvirus vec-
tors have exhibited evidence of clinical benefit. Pox-
viruses [Vaccinia (rV–), modified Vaccinia strain
Ankara (MVA), and fowlpox (rF–)] have the ability to
accept and express multiple transgenes and can thus
be engineered to express not only tumour-associated
antigens, but also various immunostimulatory mol-
ecules. Modified Vaccinia Ankara is a replication-
incompetent Vaccinia virus 24. The recombinant MVA
called TG4010 expresses both Muc1 (a higher-mo-
lecular-weight mucin that is overexpressed in most
carcinomas, including prostate carcinoma) and IL-2.
A randomized phase II study 24 of TG4010 has been
completed in prostate cancer patients with biochemi-
cal progression and no evidence of metastatic dis-
ease after local therapy (PSA doubling time of less
than 10 months). Of 38 patients, 27 (71%) had a
lengthened PSA doubling time after vaccination.
A U.S. National Cancer Institute (NCI)–sponsored
Eastern Cooperative Oncology Group randomized
phase II trial was then carried out using two different
PSA poxvirus vectors in various prime-and-boost regi-
mens: recombinant fowlpox rF–PSA (F) alone or com-
bined with rV–PSA (V) in patients (n = 64) with
biochemical progression after local therapy for pros-
tate cancer. At the 2-year follow-up, median time to
PSA or clinical progression, or both, was 9.2 months
in the cohort that received four vaccinations with F
(FFFF), 9.0 months in the cohort that received a V
vaccination after three F vaccinations (FFFV), and not
yet reached in the cohort that received three F vacci-
nations after a V vaccination (VFFF) 25. Moreover, a
recent update report 26 on the trial, with a median fol-
low-up of 50 months, revealed a median time to PSA
progression of 9.2 months and 9.1 months for the
FFFF and FFFV cohorts respectively, and 18.2 months
for the VFFF cohort.
The U.S. NCI has now developed recombinant
Vaccinia and fowlpox vectors containing the
transgenes for PSA and three human co-stimulatory
molecules (CD80, intracellular adhesion molecule 1,
and lymphocyte function–associated antigen 3, des-
ignated “TRICOM”) 27,28. Recent phase I and II trials
involving patients with metastatic and locally ad-
vanced prostate cancer have shown clinical responses
and drops in serum PSA 27,28. A multicentre random-
ized phase II study 19 in 125 patients with metastatic
androgen-independent asymptomatic prostate can-
cer did not meet its primary endpoint of progres-
sion-free survival, but the patients’ overall survival
data are currently being accumulated, with provoca-
tive results (Table II). Median overall survival thus
TABLE II Evidence of vaccine-mediated enhanced survival in prostate cancer clinical trials
Reference Patient population Study arm Patients (n) Result
Median OS:
Small et al., 2006 15 Metastatic asymptomatic HRPC APC/PAP/GM-CSF 82 25.9 mo.
Placebo 45 21.4 mo.
Simons et al., 2006 16; Metastatic asymptomatic HRPC Whole tumour cell (Gvax):
Small et al., 2006 17; and high dose 22 35 mo.
Simons et al., 2005 18 mid-/low dose 25/33 20.0/23.1 mo.
Kantoff et al., 2006 19 Metastatic HRPC PSA/TRICOM 84 24.4 mo.
Vector control 41 16.3 mo.
OS:
Petrylak et al., 2006 20 Metastatic HRPC Vaccine (APC/PAP/GM-CSF), 51 50% (approx.) at 36 mo.
then docetaxel
Control, then docetaxel 31 25% (approx.) at 36 mo.
Arlen et al., 2005 21; and Non-metastatic HRPC Vaccine (rV-PSA/B7.1, rF-PSA), 21 59% at 5 years
Madan et al., 2007 22 with or without nilutamide a
Nilutamide, with or 21 38% at 5 years
without vaccine
a Nilutamide is a second-line hormone receptor antagonist.
HRPC = hormone refractory prostate cancer; APC = antigen-presenting cell; PAP = prostatic acid phosphatase; GM-CSF = granulocyte–macro-
phage colony stimulating factor; OS = overall survival; PSA = prostate-specific antigen.CANCER VACCINE THERAPY
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far is 16.3 months for the control cohort (fowlpox
wild-type vector, n = 41) as compared with
24.4 months for patients receiving PSA–TRICOM vac-
cines (n = 84).
Vaccine trials in prostate cancer illustrate the
progress being made in clinical vaccine therapy. How-
ever, they represent only one example of the strides
being made in treating a range of human carcinomas.
Ongoing progress in pancreatic cancer 29,30, lym-
phoma 31, melanoma 32,33, lung cancer 34, and other
tumour types are also providing evidence of vaccine
efficacy in clinical trials 11.
2.3 Separating Vaccine Efficacy from Poor Clinical
Trial Design
Clinical studies have now validated what had previ-
ously been predicted by many:
• A direct correlation is evident between the can-
cer patient’s ability to mount an immune response
to a vaccine and the length of time since the
patient’s last therapy, and
• an inverse correlation is evident between the can-
cer patient’s ability to mount an immune response
to a vaccine and the patient’s number of prior
therapies 35,36.
A classic example of the distinction between a
vaccine’s potential efficacy and a poor clinical trial
design is evidenced by an ill-conceived corporate trial
in which TRICOM-based vaccines [carcinoembryonic
antigen (CEA)–Muc1–TRICOM, called Panvac-VF
(Therion Biologics, Cambridge, MA, U.S.A.)] were
administered to patients with metastatic pancreatic
cancer who had already failed prior gemcitabine
therapy 37. As many predicted, this trial failed to meet
its primary endpoint of overall survival. Poor clini-
cal trial design was clearly illustrated by
• the median overall survival of less than 3 months
in this patient population;
• the fact that only one drug combination has been
approved by the U.S. FDA for the therapy of pan-
creatic cancer (gemcitabine plus erlotinib), which
extended survival by 0.4 months; and
• twelve randomized trials of various FDA-approved
drug combinations (including bevacizumab plus
gemcitabine) have failed to extend survival in this
patient population.
Thus, failure of a phase III vaccine trial in this
patient population should foremost be considered a
failure in company-sponsored clinical trial design.
In contrast, a U.S. NCI-sponsored trial of a CEA–
TRICOM-based vaccine has recently been completed 38.
Patients (n = 58) with progressing CEA-expressing
cancers (predominantly colorectal and lung) were
accrued into several cohorts. They received rV– and
rF–CEA–TRICOM vaccines with or without GM-CSF.
Among these patients, 40% had stable disease for at
least 4 months, and 14 had prolonged stable disease
(more than 6 months). In 11 patients, serum markers
declined or stabilized, and 1 patient had a pathologic
complete response. A clear trend was also observed
in overall survival in cohorts receiving GM-CSF with
vaccine and in patients who had higher frequencies
of CEA-specific T-cell responses 38.
This protocol also revealed a novel situation:
Patients who achieved stable disease after 6 monthly
TRICOM vaccinations went on to receive vaccines every
3 months. Of those patients, 12 then progressed and
were changed back to monthly vaccinations. Subse-
quently, 6 of the 12 again reverted to disease stabili-
zation 38. This phenomenon of first stabilizing on a
therapeutic, and then progressing, and then re-stabi-
lizing when dose scheduling is changed, underscores
the paradigms that must be investigated in the use of
this relatively new therapeutic modality.
2.4 New Paradigms for Combination Therapies
The five strategies of combination therapies, which
are described in this subsection and which are being
employed with cancer vaccines, have been validated
in preclinical models, and several have provided pre-
liminary evidence of clinical benefit (Table III). As the
field matures, and if and when the U.S. FDA approves
one or more vaccines or other immune stimulants,
progress in this area will undoubtedly be accelerated.
2.4.1 Conventional Combination Therapy
In most combination therapies that use two or more
chemotherapeutic agents or a chemotherapeutic agent
and a targeted therapy, each agent works individu-
ally with the goal of additive antitumour effects.
Additive effects have been demonstrated in numer-
ous preclinical models combining vaccines with che-
motherapeutic agents. Preclinical and early clinical
studies alike have highlighted the following impor-
tant phenomenon: although vaccines are less effec-
tive in patients heavily pretreated with chemotherapy
before vaccine use, no detrimental effects in the im-
mune response to vaccine have been seen in patients
when vaccine is given in combination with chemo-
therapeutic agents such as 5-fluorouracil 39 and
docetaxel (even when given with a steroid) 40.
2.4.2 Vaccine in Combination with Agents That Affect
the Host Immune System
Many reagents that act either as immune stimulants and
adjuvants or as inhibitors of immunoregulatory cells
or molecules are currently being used in combination
with vaccines. These reagents have been shown in
multiple preclinical models to enhance the efficacy of
vaccine. Cytokines are well-proven to enhance the im-
mune response. For example, GM-CSF has now been
demonstrated in numerous clinical trials to enhanceSCHLOM et al.
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vaccine efficacy 15,18,29,30,38. Other immune stimulants
such as Bacillus Calmette–Guerin, CpG motifs, and
imiquimod are also currently being employed clinically
with vaccines. One agent that is showing great prom-
ise is the monoclonal antibody anti–cytotoxic
T lymphocyte–associated antigen 4 (anti-CTLA-4) 41,42—
CTLA-4 being the molecule expressed by antigen-primed
activated T cells. Although the exact mechanism by
which this agent works with vaccine has never been
shown clinically, preclinical studies have clearly shown
that the use of anti-CTLA-4 with vaccines results in
higher-avidity antigen-specific T cells 43.
Based on numerous preclinical studies and re-
cent clinical studies, it has become apparent that con-
trol of immune inhibitory entities will play an
important role in vaccine-mediated therapies. Pre-
clinical and clinical studies 44–46 have shown that
denileukin diftitox (a fusion protein of diphtheria
toxin and IL-2) can kill CD4/CD25/Foxp3 regulatory
T cells (“T regs”) and enhance vaccine efficacy in
inducing greater T-cell responses. The chemothera-
peutic agent cyclophosphamide has also been shown
in both preclinical and clinical studies to enhance
vaccine efficacy. Cyclophosphamide reduces not only
the number of T regs, but also their functionality 47,48.
2.4.3 Multiple Vaccine Therapies
The use of multiple vaccines may ultimately prove
advantageous because
• various types of vaccines have been shown to
enhance various entities of the host immune sys-
tem—that is, to produce greater increases in CD4,
CD8, or natural killer cells, or antibodies.
• each vaccine can carry different tumour-associ-
ated antigens.
• vaccine therapy has been associated with limited
toxicities.
• some vaccines will induce host immune responses
to the vaccine vehicle (viral vectors, for example),
limiting their continued use.
2.4.4 Dose Scheduling of Vaccine with Other Therapies
The administration of a vaccine initiates a dynamic
process of host immune response that may be ex-
ploited in subsequent therapies. This is perhaps the
most unique feature of vaccine therapy.
Among the clinical studies that have provided
evidence of this phenomenon are three randomized
clinical trials in prostate cancer. The U.S. NCI has now
completed studies with a diversified prime–boost
strategy involving priming with PSA-Vaccinia recom-
binants (rV–PSA plus rV–CD80) followed by multiple
booster vaccinations with PSA-fowlpox recombinants.
In the first trial 40, 28 patients with metastatic andro-
gen-independent prostate cancer were randomized to
receive vaccine alone or vaccine plus docetaxel. Pa-
tients on the vaccine arm alone were allowed to cross
over to receive docetaxel at the time of progression.
Median progression-free survival on docetaxel was
6.1 months for the crossover patients as compared
with 3.7 months in the patients that started on
docetaxel with the same regimen and the same pa-
tient population at the same institution. Similar find-
ings were observed in a separate trial of the
sipuleucel-T vaccine. In the randomized multicentre
sipuleucel-T study described earlier 12, patients in
both the vaccine arm (n = 51) and the placebo arm
(n = 31) went on to receive docetaxel at progression.
A striking and statistically significant (p = 0.023) in-
crease in overall survival was observed with docetaxel
treatment in patients who received the vaccine as
compared with those who received placebo
(Table  II) 20.
In another phase II trial at the U.S. NCI, 42 pa-
tients with nonmetastatic HRPC and rising levels of
PSA were randomized to receive either vaccine (rV–
PSA/CD80 prime and rF–PSA boosts; n = 21) or
nilutamide (n = 21), an androgen receptor antago-
nist. After 6 months, patients with a rising PSA and
no evidence of metastasis by radiographic criteria
TABLE III Cancer vaccine combination therapies
I. Conventional combination therapy
Each agent has independent antitumour effects
II. Vaccine plus agent or agents that augment the host immune
response
a. Immune potentiators:
• Cytokines—for example, granulocyte–macrophage
colony stimulating factor, interleukin 7,
interleukin 15
• Danger signals—for example, CpG motifs, Bacillus
Calmette–Guerin, imiquimod cream
• Androgen deprivation therapy
b. Regulation of immune inhibitors:
• Denileukin diftitox
• Cyclophosphamide
• Anti-CTLA-4 antibody
III. Multiple vaccine therapies
a. Diversified prime–boost regimens—for example,
DNA–modified Vaccinia ankara, Vaccinia–fowlpox
b. Combinations targeting various tumour antigens
IV. Phenotypic alteration of tumour cells to enhance T cell–
mediated lysis
a. Irradiation of tumour or tumour cells:
• External-beam
• Radiolabelled MAb
• Chelated radionuclide
b. Certain chemotherapeutics:
• 5-Fluorouracil, cisplatin
V. Dose scheduling of vaccine in relation to combination
therapy
Vaccines initiate a dynamic process, which can be
potentiated by subsequent therapies
Several reports suggest better clinical efficacy of
certain agents post vaccine:
• Docetaxel
• Androgen receptor antagonist (nilutamide)
• Other chemotherapeuticsCANCER VACCINE THERAPY
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were allowed to “cross over” and receive a combina-
tion of both therapies 21. From the initial randomized
population (n = 21 per cohort), 5-year overall sur-
vival was 38% for the patients who received niluta-
mide first (nilutamide alone or nilutamide and then
vaccine) as compared with 59% for the patients who
received vaccine first (vaccine alone or nilutamide
plus vaccine; Table II) 22.
The foregoing trials and others 49,50 at different
institutions using different vaccines and patient popu-
lations have all provided evidence of the same phe-
nomenon: patients who receive vaccine (and who
mount immune responses as a result) have enhanced
outcomes with subsequent therapies. This phenom-
enon may be attributable to one or a combination of
factors:
• The subsequent therapy may be reducing sup-
pressor cell populations, thus allowing for en-
hancement of earlier-established T-cell responses.
• The subsequent therapies may be lysing some
tumour cells that are then, as a consequence of
cross-priming, activating relatively dormant
T cells to elicit an antitumour response.
• The subsequent therapy may alter the phenotype
of tumour cells or, as in androgen deprivation
therapy, enhance T-cell levels (next subsection).
2.4.5 Phenotype Alterations in Tumour Cells
Yet another paradigm to exploit in vaccine combina-
tion therapies is the phenomenon of certain standard-
of-care therapeutics actually altering the phenotype
of tumour cells to render them more susceptible to
lysis mediated by T cells. Phenotype alteration has
been shown in a series of preclinical studies involv-
ing murine models in vivo, and in a large series of
human tumour cell lines in vitro 51–53. Sublethal doses
of X-irradiation delivered to tumours have been
shown to upregulate one or a combination of tumour-
associated antigens, fas, or adhesion molecules, or to
downregulate anti-apoptotic genes (or both), subse-
quently rendering the phenotypically altered tumour
cells more susceptible to antigen-specific T cell–
mediated lysis. Similar alterations of tumour-cell
phenotype and subsequent susceptibility to T cell–
mediated lysis have also been induced by sublethal
doses of certain chemotherapeutic agents 53. These
findings may ultimately lead to another paradigm shift
in vaccine combination therapies: That is, when a drug
or radiation treatment fails to produce a response be-
cause of inability to lyse tumour cells, such a treat-
ment may continue to be used with vaccine therapy
because of its ability to augment vaccine-
induced T-cell lysis of tumour.
3. CONCLUSIONS
Here, we have reviewed only a few of the vaccine
vehicles that are currently being used with evidence
of clinical benefit. Allogeneic whole tumour cells,
peptide- or protein-pulsed antigen-presenting cells
(including dendritic cells), recombinant DNA and viral
vectors, and recombinant Saccharomyces (yeast) are
all in active clinical trial development. Moreover, a
vast array of newly defined potential tumour-associ-
ated targets are available for cancer vaccine devel-
opment, including those involved in the neoplastic
or tumour progression processes.
In our view, the field of therapeutic cancer vac-
cines is alive and thriving. As new paradigms in clini-
cal trial design and endpoints and in combination
therapies are realized, cancer vaccines may ultimately
become a standard component in the management of
several types of cancer.
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